Lateral Process Fracture of the Talus: A Case Series and Review of the Literature.

J Foot Ankle Surg

Surgeon, Trauma Unit, Amsterdam University Medical Center, Location AMC, Amsterdam, the Netherlands. Electronic address:

Published: June 2020

Fracture of the lateral process of the talus (LPFT) is a frequently overlooked injury that can lead to severe complaints if not treated adequately. The aim of this study was to evaluate treatment and long-term outcomes of LPFT through a review of the literature. Furthermore, we propose a modified classification based on severity and intra- or extra-articular location of LPFT. Patients diagnosed with LPFT and treated at a Level 1 trauma center between 2001 and 2018 were included. Fracture and treatment characteristics were recorded in combination with functional outcome and quality of life after a mean follow-up of 5.5 (range 0.8 to 17.2) years. A comprehensive literature search was performed to identify all case series regarding patients with LPFT; 36 patients were included. According to our modified classification, 1 patient had type 1A (2.8%), 6 patients had type 1B (16.7%), 10 patients had type 2 (27.8%), 11 patients had type 3 (30.6%), 6 patients had type 4A (16.7%), and 2 patients had type 4B (5.6%). Twenty-eight patients underwent operative fixation (78%). The median American Orthopaedic Foot and Ankle Society Hindfoot Score was 75 (range 12 to 100). The median Foot Function Index was 2 (range 0 to 9). The median score for the EuroQol-5D was 0.8 (range -0.5 to 1), and the median score for health status component was 75 (range 30 to 98). There is some room for conservative treatment of LPFT; however, we strongly believe that this should be considered only for nondisplaced, small-fragment, and extra-articular fractures. Surgical treatment leads to an overall good (long-term) outcome.

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.jfas.2019.02.003DOI Listing

Publication Analysis

Top Keywords

patients type
20
patients
9
lateral process
8
case series
8
review literature
8
modified classification
8
lpft patients
8
type 167%
8
167% patients
8
median score
8

Similar Publications

Excessive daytime sleepiness and its predictors among type 2 diabetes mellitus patients at central ethiopia.

Sci Rep

December 2024

Department of Pediatrics and Child Health Nursing, College of Medicine and Health Sciences, Injibara University, Injibara, Ethiopia.

Excessive daytime sleepiness is a common finding among type 2 diabetes mellitus patients. However there is scarce data that shows the magnitude of excessive daytime sleepiness, & its association with type 2 diabetes mellitus. Hence, the study aimed to assess the prevalence of excessive daytime sleepiness and its associated factors among type 2 diabetes mellitus patients at Wolkite University Specialized Hospital.

View Article and Find Full Text PDF

Warfarin is the most widely used oral anticoagulant in clinical practice. The cytochrome P450 2C9 (CYP2C9), vitamin K epoxide reductase complex 1 (VKORC1), and cytochrome P450 4F2 (CYP4F2) genotypes are associated with warfarin dose requirements in China. Accurate genotyping is vital for obtaining reliable genotype-guided warfarin dosing information.

View Article and Find Full Text PDF

Sickle cell anemia (SCA) is a monogenic blood disease with complex and multifactorial pathophysiology. The endocannabinoid system (ECS) could be a candidate for modulating SCA complications, such as priapism, as it has demonstrated an essential role in hematopoiesis, platelet aggregation, and immune responses. We evaluated the association of ECS-related single nucleotide polymorphisms (SNP) (FAAH rs324420, MAGL rs604300, CNR1 rs7766029, and CNR2 rs35761398) with priapism in a Brazilian SCA cohort.

View Article and Find Full Text PDF

BAY 2413555 is a novel selective and reversible positive allosteric modulator of the type 2 muscarinic acetylcholine (M2) receptor, aimed at enhancing parasympathetic signaling and restoring cardiac autonomic balance for the treatment of heart failure (HF). This study tested the safety, tolerability and pharmacokinetics of this novel therapeutic option. REMOTE-HF was a multicenter, double-blind, randomized, placebo-controlled, phase Ib dose-titration study with two active arms.

View Article and Find Full Text PDF

Pathogenic activating mutations in the fibroblast growth factor receptor 3 (FGFR3) drive disease maintenance and progression in urothelial cancer. 10-15% of muscle-invasive and metastatic urothelial cancer (MIBC/mUC) are FGFR3-mutant. Selective targeting of FGFR3 hotspot mutations with tyrosine kinase inhibitors (e.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!